New developments in the management of COPD: Clinical utility of indacaterol 75 μg

International Journal of COPD

Volumn 9, Issue , 2013, Pages 1-7

  Steiropoulos, Paschalis ^a   Archontogeorgis, Kostas ^a   Nena, Evangelia ^a   Bouros, Demosthenes ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Chronic obstructive pulmonary disease; Indacaterol; Long acting bronchodilators

Indexed keywords

BRONCHODILATING AGENT; BUDESONIDE PLUS FORMOTEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL XINAFOATE; FORMOTEROL; INDACATEROL; PLACEBO; SALMETEROL; TIOTROPIUM BROMIDE;

AIRWAY OBSTRUCTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; COMPARATIVE EFFECTIVENESS; COUGHING; DISEASE EXACERBATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DYSPNEA; FORCED EXPIRATORY VOLUME; HEADACHE; HEALTH STATUS; HUMAN; INFECTION; MUSCULOSKELETAL DISEASE; REVIEW; RHINOPHARYNGITIS; TREATMENT DURATION;

CHRONIC OBSTRUCTIVE PULMONARY DISEASE; INDACATEROL; LONG-ACTING BRONCHODILATORS; Β2-AGONISTS;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; BRONCHOCONSTRICTION; BRONCHODILATOR AGENTS; DRUG ADMINISTRATION SCHEDULE; HUMANS; INDANS; LUNG; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84890348560     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S24940     Document Type: Review

References (50)

1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD. Updated 2013. Available from: http://www. goldcopd. org/uploads/users/files/GOLD_Report_2013_Feb20. pdf. Accessed July 8, 2013.
2. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007; 370(9589): 765-773.
3. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006; 3(11): e442.
4. Hanania NA, Marciniuk DD. A unified front against COPD: clinical practice guidelines from the American College of Physicians, the American College of Chest Physicians, the American Thoracic Society, and the European Respiratory Society. Chest. 2011; 140(3): 565-566.
5. Maltais F, Dennis N, Chan CK. Rationale for earlier treatment in COPD: a systematic review of published literature in mild-to-moderate COPD. COPD. 2013; 10(1): 79-103.
6. Geitona M, Hatzikou M, Steiropoulos P, Alexopoulos EC, Bouros D. The cost of COPD exacerbations: a university hospital-based study in Greece. Respir Med. 2011; 105(3): 402-409.
7. Mahler DA. The effect of inhaled beta2-agonists on clinical outcomes in chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2002; 110(Suppl 6): S298-S303.
8. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14. 5-year mortality: a randomized clinical trial. Ann Intern Med. 2005; 142(4): 233-239.
9. Naunheim KS, Wood DE, Mohsenifar Z, et al. Long-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group. Ann Thorac Surg. 2006; 82(2): 431-443.
10. Steiropoulos P, Tzouvelekis A, Bouros D. Formoterol in the management of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2008; 3(2): 205-215.
11. Chowdhury BA, Seymour SM, Michele TM, Durmowicz AG, Liu D, Rosebraugh CJ. The risks and benefits of indacaterol-the FDA's review. N Engl J Med. 2011; 365(24): 2247-2249.
12. Cazzola M, Page CP, Calzetta L, Matera MG. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev. 2012; 64(3): 450-504.
13. Roig J, Hernando R, Mora R. Indacaterol, a novel once daily inhaled beta2-adrenoreceptor agonist. Open Respir Med J. 2009; 3: 27-30.
14. Steiropoulos P, Papanas N, Nena E, Bouros D. Indacaterol: a new long-acting β2-agonist in the management of chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2012; 13(7): 1015-1029.
15. Han J, Dai L, Zhong N. Indacaterol on dyspnea in chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized placebo-controlled trials. BMC Pulm Med. 2013; 13: 26.
16. Feldman GJ. Improving the quality of life in patients with chronic obstructive pulmonary disease: focus on indacaterol. Int J Chron Obstruct Pulmon Dis. 2013; 8: 89-96.
17. Cope S, Capkun-Niggli G, Gale R, et al. Efficacy of once-daily indacaterol relative to alternative bronchodilators in COPD: a patient-level mixed treatment comparison. Value Health. 2012; 15(3): 524-533.
18. Rodrigo GJ, Neffen H. Comparison of indacaterol with tiotropium or twice-daily long-acting β-agonists for stable COPD: a systematic review. Chest. 2012; 142(5): 1104-1110.
19. Battram C, Charlton SJ, Cuenoud B, et al. In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5, 6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action. J Pharmacol Exp Ther. 2006; 317(2): 762-770.
20. Scola AM, Loxham M, Charlton SJ, Peachell PT. The long-acting beta-adrenoceptor agonist, indacaterol, inhibits IgE-dependent responses of human lung mast cells. Br J Pharmacol. 2009; 158(1): 267-276.
21. Naline E, Trifilieff A, Fairhurst RA, Advenier C, Molimard M. Effect of indacaterol, a novel long-acting beta2-agonist, on isolated human bronchi. Eur Respir J. 2007; 29(3): 575-581.
22. Sturton RG, Trifilieff A, Nicholson AG, Barnes PJ. Pharmacological characterization of indacaterol, a novel once daily inhaled 2 adrenoceptor agonist, on small airways in human and rat precision-cut lung slices. J Pharmacol Exp Ther. 2008; 324(1): 270-275.
23. Pearlman DS, Greos L, LaForce C, Orevillo CJ, Owen R, Higgins M. Bronchodilator efficacy of indacaterol, a novel once-daily beta2-agonist, in patients with persistent asthma. Ann Allergy Asthma Immunol. 2008; 101(1): 90-95.
24. Magnussen H, Verkindre C, Jack D, et al. Indacaterol once-daily is equally effective dosed in the evening or morning in COPD. Respir Med. 2010; 104(12): 1869-1876.
25. Lombardi D, Cuenoud B, Kramer SD. Lipid membrane interactions of indacaterol and salmeterol: do they influence their pharmacological properties? Eur J Pharm Sci. 2009; 38(5): 533-547.
26. Cazzola M, Calzetta L, Matera MG. β(2)-adrenoceptor agonists: current and future direction. Br J Pharmacol. 2011; 163(1): 4-17.
27. Westwood M, Bourbeau J, Jones PW, Cerulli A, Capkun-Niggli G, Worthy G. Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review. Respir Res. 2011; 12: 40.
28. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008; 31(2): 416-469.
29. Kerwin EM, Gotfried MH, Lawrence D, Lassen C, Kramer B. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged $40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies. Clin Ther. 2011; 33(12): 1974-1984.
30. Barnes PJ, Pocock SJ, Magnussen H, et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulm Pharmacol Ther. 2010; 23(3): 165-171.
31. Cope S, Zhang J, Williams J, Jansen JP. Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: a study level and a patient level network meta-analysis. BMC Pulm Med. 2012; 12: 29.
32. Dahl R, Chung KF, Buhl R, et al. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010; 65(6): 473-479.
33. Donohue JF, Fogarty C, Lotvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010; 182(2): 155-162.
34. Kornmann O, Dahl R, Centanni S, et al. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J. 2011; 37(2): 273-279.
35. Renard D, Looby M, Kramer B, Lawrence D, Morris D, Stanski DR. Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches. Respir Res. 2011; 12: 54.
36. Cope S, Kraemer M, Zhang J, Capkun-Niggli G, Jansen JP. Efficacy of indacaterol 75 mug versus fixed-dose combinations of formoterol-budesonide or salmeterol-fluticasone for COPD: a network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2012; 7: 415-420.
37. Witek TJ Jr, Mahler DA. Meaningful effect size and patterns of response of the transition dyspnea index. J Clin Epidemiol. 2003; 56(3): 248-255.
38. Gotfried MH, Kerwin EM, Lawrence D, Lassen C, Kramer B. Efficacy of indacaterol 75 μg once-daily on dyspnea and health status: results of two double-blind, placebo-controlled 12-week studies. COPD. 2012; 9(6): 629-636.
39. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St George's Respiratory Questionnaire. Am Rev Respir Dis. 1992; 145(6): 1321-1327.
40. Kerwin EM, Williams J. Indacaterol 75 μg once daily for the treatment of patients with chronic obstructive pulmonary disease: a North American perspective. Ther Adv Respir Dis. 2013; 7(1): 25-37.
41. Donohue JF, Singh D, Kornmann O, Lawrence D, Lassen C, Kramer B. Safety of indacaterol in the treatment of patients with COPD. Int J Chron Obstruct Pulmon Dis. 2011; 6: 477-492.
42. 2-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest. 2011; 140(1): 68-75.
43. Rossi A, Polese G. Indacaterol: a comprehensive review. Int J Chron Obstruct Pulmon Dis. 2013; 8: 353-363.
44. Price D, Gray A, Gale R, et al. Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD. Respir Med. 2011; 105(11): 1635-1647.
45. Price D, Asukai Y, Ananthapavan J, Malcolm B, Radwan A, Keyzor I. A UK-based cost-utility analysis of indacaterol, a once-daily maintenance bronchodilator for patients with COPD, using real world evidence on resource use. Appl Health Econ Health Policy. 2013; 11(3): 259-274.
46. Rossi A, Centanni S, Cerveri I, et al. Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium. Respir Med. 2012; 106(1): 84-90.
47. Beeh KM, Wagner F, Khindri S, Drollmann AF. Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD. COPD. 2011; 8(5): 340-345.
48. Mahler DA, D'Urzo A, Bateman ED, et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax. 2012; 67(9): 781-788.
49. van Noord JA, Buhl R, Laforce C, et al. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax. 2010; 65(12): 1086-1091.
50. Worth H, Chung KF, Felser JM, Hu H, Rueegg P. Cardio-and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir Med. 2011; 105(4): 571-579.